US 12,303,492 B2
Compounds for treating TNBC
Thomas Jorg Mehrling, Basel (CH)
Assigned to Purdue Pharma L.P., Stamford, CT (US)
Filed by Purdue Pharma L.P., Stamford, CT (US)
Filed on Sep. 12, 2023, as Appl. No. 18/244,913.
Application 18/244,913 is a continuation of application No. 17/885,696, filed on Aug. 11, 2022, granted, now 11,786,509.
Application 17/885,696 is a continuation of application No. 16/621,896, granted, now 11,413,276, issued on Aug. 16, 2022, previously published as PCT/EP2018/065662, filed on Jun. 13, 2018.
Claims priority of application No. 1709406.1 (GB), filed on Jun. 13, 2017.
Prior Publication US 2024/0139155 A1, May 2, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4184 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 31/502 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/4184 (2013.01) [A61P 35/00 (2018.01); A61K 9/0019 (2013.01); A61K 31/502 (2013.01); A61K 45/06 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A method of treating advanced or metastatic triple negative breast cancer (TNBC) in a patient in need thereof, comprising administering to said patient tinostamustine or a pharmaceutically acceptable salt thereof, at a dosage range from 60 mg/m2 to 100 mg/m2 body surface area of said patient through infusion, in combination with a radiotherapy, wherein the TNBC is basal-like 1 (BL1) subtype, BRCA-1 wildtype, or a combination thereof.